Artiva Biotherapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Artiva Biotherapeutics, Inc. (ARTV) reported Increase (Decrease) in Contract with Customer, Liability of -$26.53 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-03-24
- Artiva Biotherapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was -$1.31M.
- Artiva Biotherapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was -$23.73M.
- Artiva Biotherapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$26.53M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$25.05M derived: sum of 2 quarters · filed 2025-03-24 | -$26.53M 10-K · filed 2025-03-24 | |
| 2023-09-30 | -$23.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$25.21M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$1.48M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |